Testosterone
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Testosterone
Testosterone: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Testosterone, so there is currently no new predicted indication. The uses recorded for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 15 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| acquired pituitary hormone deficiency |
| androgen insensitivity syndrome |
| combined pituitary hormone deficiencies, genetic form |
| congenital hypogonadotropic hypogonadism |
| cryptorchidism |
| eunuchism |
| hypogonadism |
| hypogonadism, male |
| hypogonadotropic hypogonadism |
| hypogonadotropic hypogonadism with or without anosmia |
| hypogonadotropic hypogonadism-frontoparietal alopecia syndrome |
| hypopituitarism |
| isolated congenital growth hormone deficiency |
| isolated growth hormone deficiency |
| kallmann syndrome |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10378F | AndroForte 5 | Transdermal cream 50 mg per mL, 50 mL | Valid |
Safety Considerations
- Drug Interactions: 100 interactions were identified, and the 20 shown in the data compiled for this report are all rated Moderate. The main groups are:
- Corticosteroids: hydrocortisone, betamethasone, budesonide, dexamethasone
- Sulfonylureas: acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide
- Insulins: human, aspart, degludec, detemir, glargine, glulisine and others
- Other: aprepitant, topical calcitriol
- Conditions flagged for caution (drug-disease associations in the model’s knowledge base, not taken from the product label): hypertension, epilepsy, kidney disease, liver disease, congestive heart failure, diabetes mellitus, asthma, hypothyroidism, systemic lupus erythematosus, hypercalcaemia, benign prostatic hyperplasia, hypertriglyceridaemia, female breast carcinoma, thrombophlebitis and uterine leiomyoma.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as label-based data were not available for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.